AOD-9604 for Fat Loss: Stubborn Fat, Body Composition, and Real-World Results (2026)

AOD-9604 for Fat Loss: What the Research Actually Shows

AOD-9604 is a synthetic 16-amino acid peptide fragment derived from amino acids 176 to 191 of human growth hormone. It targets stubborn fat by activating beta-3 adrenergic receptors in adipose tissue, triggering lipolysis and inhibiting lipogenesis, without affecting growth hormone receptors, IGF-1 levels, or insulin sensitivity.

If you have been lifting for years, eating clean, and the visceral belly fat still will not shift, you are not imagining things. Subcutaneous fat around the abdomen responds differently to caloric deficit than fat elsewhere. It resists mobilisation through ordinary mechanisms. AOD-9604 was designed, in part, to address exactly this problem.

This guide covers the mechanism, the human clinical trial data (including the trial that ended pharmaceutical development), the visceral selectivity evidence, the dosing range from research protocols, and an honest appraisal of where AOD-9604 fits inside a high-performance protocol.

The Science Behind AOD-9604: A Fragment Engineered for Lipolysis

AOD-9604 was developed at Monash University and commercialised by Metabolic Pharmaceuticals Ltd in Australia during the 1990s. Researchers isolated the C-terminal fragment of hGH specifically because that region drives fat oxidation, then modified it to activate lipolytic pathways while eliminating the growth-promoting and glucose-disrupting properties of full-length growth hormone.

Human growth hormone has two distinct functional domains. The N-terminal region drives growth-promoting effects: IGF-1 secretion, nitrogen retention, muscle hypertrophy. The C-terminal fragment, amino acids 176 to 191, handles lipolysis. AOD-9604 is that fragment, modified to increase stability.

The mechanism operates through selective beta-3 adrenergic receptor activation in adipose tissue. Beta-3 receptors are the specific adrenergic pathway responsible for thermogenesis and lipolysis in fat cells, particularly in visceral depots. Full-length hGH activates this pathway but also hits the growth hormone receptor, stimulates IGF-1 production, and can impair insulin sensitivity at pharmacological doses. AOD-9604 isolates the beta-3 pathway and leaves the rest alone.

Early preclinical studies confirmed the mechanism. Heffernan et al. 2001 demonstrated that AOD-9604 reduces body weight gain, increases fat oxidation, and stimulates lipolysis in obese mice without activating the hGH receptor or causing hyperglycemia. Ng et al. 2001 showed that oral AOD-9604 at 500 mcg/kg in obese Zucker rats reduced body weight gain by over 50% versus control, with significantly increased adipose tissue lipolytic activity and no adverse effect on insulin sensitivity.

That last point matters. Chronically elevated hGH causes insulin resistance. AOD-9604 produces lipolysis without that metabolic liability, which matters considerably for men running extended fat-loss phases.

Human Clinical Trial Data: The 2.6 kg Signal and the Failed Phase IIb

AOD-9604 completed six randomised, double-blind, placebo-controlled clinical trials involving approximately 900 participants. The clearest positive signal came from a 12-week Phase IIb trial showing 2.6 kg weight loss at 1 mg/day versus 0.8 kg placebo. Development was halted in 2007 after a longer 24-week trial in 536 subjects failed to reach statistical significance.

The 12-week trial data is the most cited. Srinivasan et al. 2011 confirmed the result: subjects receiving AOD-9604 at 1 mg per day lost an average of 2.6 kg compared to 0.8 kg in the placebo group over 12 weeks. That is a meaningful separation on a compound with no appetite suppression mechanism and no stimulant effect.

The data also revealed something unexpected: AOD-9604 weight loss is not dose-dependent. Subjects on 10 mg per day showed a smaller reduction than those on 1 mg per day. Rodgers et al. 2013 discuss this pattern in the context of pharmaceutical development: the non-dose-dependent response curve complicates titration and likely contributed to the inconsistent results seen in the larger trial.

The 24-week Phase IIb trial enrolled 536 obese subjects. Results failed to demonstrate statistically significant weight loss versus placebo across the full population. Rodgers et al. 2013 document the development termination in 2007. This is the honest context any serious AOD-9604 protocol needs to account for: the pharmaceutical pathway failed, not because of safety, but because the effect size was insufficient to clear regulatory bars in a heterogeneous obese population.

That population context is critical. The clinical trials enrolled people who were clinically obese. The question for a high-performance user in reasonable metabolic health, carrying stubborn residual fat, is different. The modest population-level effect may not accurately reflect what happens in a leaner individual with specific adipose targets.

Visceral Fat Selectivity: The 4.6x Finding

The most compelling finding in AOD-9604 research is not total weight loss but regional selectivity. A 2005 study published in the Journal of Clinical Endocrinology and Metabolism found that subjects administered AOD-9604 lost visceral abdominal fat at rates 4.6 times higher than subcutaneous limb fat, even with identical caloric restriction across groups.

This finding is mechanistically plausible. Visceral adipose tissue has higher beta-3 adrenergic receptor density than subcutaneous depots in other body regions. Activation of that pathway preferentially mobilises visceral fat. The implication is that AOD-9604 may be doing targeted work within the fat depot that most resists ordinary caloric deficit intervention.

For the reader this article is written for, that is the relevant signal. If your total body weight is not the primary target and visceral accumulation around the lower abdomen is the actual problem, a compound that preferentially mobilises that depot is mechanistically useful in ways that weight loss averages from obese trial populations do not capture.

The mechanism is supported by the beta-3 receptor biology. Heffernan et al. 2001 confirmed that AOD-9604 stimulates lipolysis without activating the growth hormone receptor. Kopelman 2006 includes AOD-9604 in a regulatory pipeline review as a growth hormone fragment that specifically increases adipose tissue breakdown. The visceral selectivity finding complements that mechanism rather than contradicting it.

AOD-9604 vs Full-Length HGH: Why the Fragment Matters

AOD-9604 does not activate the growth hormone receptor, does not elevate IGF-1, and does not impair insulin sensitivity. These are not minor distinctions. Full-length hGH at pharmacological doses causes fluid retention, carpal tunnel, insulin resistance, and potential for long-term IGF-1-driven proliferative effects. AOD-9604 produces the lipolytic benefit without those risks.

This distinction is the entire point of the compound. Pharmaceutical researchers were not trying to create a weaker version of growth hormone. They were trying to isolate the fat-burning domain and remove everything else. Metolius Health 2026 summarises the receptor binding profile clearly: AOD-9604 binds beta-3 adrenergic receptors, not the growth hormone receptor. IGF-1 does not change. Glucose metabolism does not change. Insulin sensitivity is preserved.

For comparison, GH secretagogues like CJC-1295 and Ipamorelin elevate endogenous growth hormone production and therefore do drive IGF-1 increases over time. That is part of their benefit for body composition and recovery but also part of their risk profile. AOD-9604 operates through a different mechanism entirely and should not be conflated with growth hormone protocols or GH secretagogue stacks.

The absence of IGF-1 elevation also means the theoretical long-term cancer risk associated with elevated IGF-1 does not apply to AOD-9604 in the same way. This is not a safety claim; it is a mechanistic observation that reduces one category of theoretical concern that exists with full-length hGH use.

Dosing Protocols in Research Literature

Clinical trials tested AOD-9604 across a broad dose range including 250 mcg, 500 mcg, and 1 mg daily. Six randomised trials in approximately 900 participants established a favourable safety profile across this range. Research protocols most commonly reference 250 to 500 mcg per day administered subcutaneously, typically in the morning before eating or training.

Seekpeptides 2026 synthesises the dosing literature: the 250 to 500 mcg daily range covers the effective window established across six RCTs. The clinical trial that showed the clearest positive result used 1 mg per day. Importantly, going above 1 mg did not improve outcomes and in the 10 mg group produced less effect, suggesting a receptor saturation or desensitisation effect at high doses.

Most research protocols apply the dose subcutaneously in the lower abdomen, rotating injection sites. Morning dosing, fasted or 30 to 60 minutes before training, is common in published case series. There is no published human data on nasal or oral bioavailability sufficient to recommend those routes with confidence, despite preclinical evidence of oral activity in rats at very high weight-adjusted doses.

Cycle length in research contexts has ranged from 12 to 24 weeks. The 12-week period produced the strongest positive signal. The 24-week trial did not extend benefits proportionally. Most practitioners in the research literature work in 12-week blocks with structured re-evaluation.

Always work with a qualified clinician before making changes to your health protocol. The dosing ranges above are drawn from research literature and are not personalised recommendations.

Safety Profile: Six Trials, 900 Participants

AOD-9604 has one of the more thoroughly characterised safety profiles among research peptides, by virtue of its pharmaceutical development history. Six randomised, double-blind, placebo-controlled trials involving approximately 900 participants showed side effects indistinguishable from placebo. No serious adverse events were reported in published trial data.

Seekpeptides 2026 documents that the six-trial safety dataset represents an unusually robust human safety record for a research peptide that never reached pharmaceutical approval. The compound cleared multiple regulatory safety reviews during its clinical development phase.

Injection site reactions are the most commonly reported issue in protocol case series: minor redness, transient irritation from inconsistent rotation. These are procedural rather than pharmacological in origin.

The insulin sensitivity data from Ng et al. 2001 in preclinical models is reassuring for users concerned about glucose metabolism. Unlike growth hormone or some growth hormone secretagogues, AOD-9604 showed no adverse effect on insulin sensitivity even with chronic treatment.

The compound does not appear on WADA's prohibited list as of 2026 for most sports, though regulatory status varies by jurisdiction and evolves. Confirm current status with your sport's anti-doping authority before use if competition is relevant.

Stack Considerations and Practical Context

AOD-9604 is most relevant for individuals in reasonable metabolic health who have residual stubborn fat, particularly visceral abdominal accumulation, that resists caloric deficit and training. It is not a primary obesity treatment and does not replace diet, training, or sleep. It works on the lipolytic mechanism; everything else must be handled by the surrounding protocol.

AOD-9604 does not suppress appetite, does not affect energy expenditure, and does not alter hormonal axes beyond its targeted lipolytic activity. This means it cannot compensate for a poor dietary environment. The 2.6 kg signal from the 12-week trial occurred in subjects following caloric guidance. Without that foundation, the mechanism has nothing useful to act on.

Stacking considerations: because AOD-9604 operates through beta-3 adrenergic receptors rather than the GH/IGF-1 axis, it can theoretically complement GH secretagogues without duplicating mechanisms. Users running CJC-1295 and Ipamorelin for body composition and recovery may find AOD-9604 adds targeted visceral mobilisation that the secretagogue stack does not address directly. However, stack interactions are not studied in clinical trials and require careful clinical oversight.

BPC-157 and TB-500 are often run alongside body composition peptides for connective tissue support during aggressive training phases. AOD-9604 does not interact with those mechanisms. These are parallel, non-competing pathways.

With AOD-9604, the supplier matters as much as the dose. We only list sources that publish an independent, per-batch certificate of analysis. See the ones that clear it.

For a deeper look at how AOD-9604 fits within the broader growth hormone fragment landscape, see our guide on CJC-1295 and Ipamorelin protocols.

Who Is AOD-9604 For?

AOD-9604 is best suited to men in reasonable metabolic health who carry persistent visceral or lower-abdominal fat that has not responded to sustained caloric deficit and structured training. It is not a first-line intervention. It is a targeted tool for a specific remaining problem.

The compound is not appropriate as a primary weight loss intervention for people who are clinically obese. The Phase IIb trial failed precisely in that population. If total body mass is the target, the primary drivers (diet, training, sleep, hormonal optimisation) have to do the heavy lifting.

The ideal candidate profile, drawn from the research literature, looks like this: training consistently for at least 12 months, nutrition structured around a moderate caloric deficit or maintenance, hormonal health assessed and optimised, stubborn visceral fat remains as the primary remaining target. In that context, AOD-9604 adds a mechanistically specific tool that acts through a pathway ordinary interventions do not address.

Men who have already reviewed their options within the growth hormone secretagogue space and want targeted fat mobilisation without IGF-1 elevation or insulin sensitivity disruption are the population this compound was designed for. The clinical trial history is honest about the limitations. The visceral selectivity data is the signal worth paying attention to.

References

• Heffernan et al. 2001: Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. PubMed.
• Ng et al. 2001: Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. PubMed.
• Srinivasan et al. 2011: Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy. PMC.
• Rodgers et al. 2013: Obesity Pharmacotherapy: Current Perspectives and Future Directions. PMC.
• Kopelman 2006: Obesity drugs in clinical development. PubMed.
• Metolius Health 2026: AOD-9604 Fat Loss Peptide: The Growth Hormone Fragment Targeting Stubborn Fat.
• Seekpeptides 2026: AOD 9604 dosage: complete protocol guide for fat loss.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.